Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Disseminated tumor cells (DTCs) from bone marrow (BM) are a surrogate of minimal residual disease (MRD) in primary breast cancer (PBC) patients and associated with an adverse prognosis. However, BM sampling is an invasive procedure. Although there is growing evidence that circulating tumor cells (CTCs) from the blood are also suitable for monitoring MRD, data on the simultaneous detection of DTCs and CTCs are limited. Materials and Methods We determined the presence of DTCs using immunocytochemistry and the pan-cytokeratin antibody A45-B/B3. CTCs were determined simultaneously using a reverse transcription- polymerase chain reaction–based assay (AdnaTest Breast Cancer) and CellSearch (at least one CTC per 7.5 mL blood). We compared the detection of DTCs and CTCs and evaluated their impact on disease-free and overall survival. Results Of 585 patients, 131 (22%) were positive for DTCs; 19 of 202 (9%) and 18 of 383 (5%) patients were positive for CTCs, as shown by AdnaTest and CellSearch, respectively. No significant association was observed between DTCs and CTCs (p=0.248 and p=0.146 as shown by AdnaTest and CellSearch, respectively). The presence of DTCs (p=0.046) and the presence of CTCs as shown by CellSearch (p=0.007) were predictive of disease-free survival. Conclusion Our data confirm the prognostic relevance of DTCs and CTCs in patients with PBC. As we found no significant relationship between DTCs and CTCs, prospective trials should include their simultaneous detection. Within those trials, the question of whether or not DTCs and CTCs are independent subpopulations of malignant cell clones should be determined by molecular characterization.
Abstract
Purpose Disseminated tumor cells (DTCs) from bone marrow (BM) are a surrogate of minimal residual disease (MRD) in primary breast cancer (PBC) patients and associated with an adverse prognosis. However, BM sampling is an invasive procedure. Although there is growing evidence that circulating tumor cells (CTCs) from the blood are also suitable for monitoring MRD, data on the simultaneous detection of DTCs and CTCs are limited. Materials and Methods We determined the presence of DTCs using immunocytochemistry and the pan-cytokeratin antibody A45-B/B3. CTCs were determined simultaneously using a reverse transcription- polymerase chain reaction–based assay (AdnaTest Breast Cancer) and CellSearch (at least one CTC per 7.5 mL blood). We compared the detection of DTCs and CTCs and evaluated their impact on disease-free and overall survival. Results Of 585 patients, 131 (22%) were positive for DTCs; 19 of 202 (9%) and 18 of 383 (5%) patients were positive for CTCs, as shown by AdnaTest and CellSearch, respectively. No significant association was observed between DTCs and CTCs (p=0.248 and p=0.146 as shown by AdnaTest and CellSearch, respectively). The presence of DTCs (p=0.046) and the presence of CTCs as shown by CellSearch (p=0.007) were predictive of disease-free survival. Conclusion Our data confirm the prognostic relevance of DTCs and CTCs in patients with PBC. As we found no significant relationship between DTCs and CTCs, prospective trials should include their simultaneous detection. Within those trials, the question of whether or not DTCs and CTCs are independent subpopulations of malignant cell clones should be determined by molecular characterization.
참고문헌 (25)
- Braun S, "A pooled analysis of bone marrow micrometastasis in breast cancer", N Engl J Med, 353, pp.793~802 (2005)
- Gebauer G, "Epithelial cells in bone marrow of breast cancer patients at time of primary surgery : clinical outcome during long-term follow-up", J Clin Oncol, 19, pp.3669~3674 (2001)
- Hartkopf AD, "Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients : results from a large single-centre analysis", Eur J Cancer, 50, pp.2550~2559 (2014)
- Lucci A, "Circulating tumour cells in non-metastatic breast cancer : a prospective study", Lancet Oncol, 13, pp.688~695 (2012)
- Rack B, "Circulating tumor cells predict survival in early average-to-high risk breast cancer patients", J Natl Cancer Inst, 106 (2014)
- Molloy TJ, "The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients", Breast Cancer Res, 13, pp.61~ (2011)
- Franken B, "Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer", Breast Cancer Res, 14, pp.133~ (2012)
- Nora Dickson M, "Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device", Biomicrofluidics, 5, pp.34119~ (2011)
- Cristofanilli M, "Circulating tumor cells, disease progression, and survival in metastatic breast cancer", N Engl J Med, 351, pp.781~791 (2004)
- Schindlbeck C, "Comparison of circulating tumor cells(CTC)in peripheral blood and disseminated tumor cells in the bone marrow(DTC-BM)of breast cancer patients", J Cancer Res Clin Oncol, 139, pp.1055~1062 (2013)
- Hartkopf AD, "Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer", Breast Cancer Res Treat, 147, pp.345~351 (2014)
- Fehm T, "A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation", Cancer, 107, pp.885~892 (2006)
- Klein CA, "Parallel progression of primary tumours and metastases", Nat Rev Cancer, 9, pp.302~312 (2009)
- Fischer JC, "Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients", Proc Natl Acad Sci U S A, 110, pp.16580~16585 (2013)
- Krishnamurthy S, "Detection of minimal residual disease in blood and bone marrow in early stage breast cancer", Cancer, 116, pp.3330~3337 (2010)
- Slade MJ, "Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment", Br J Cancer, 100, pp.160~166 (2009)
- Bidard FC, "Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer", Ann Oncol, 21, pp.729~733 (2010)
- Gruber I, "Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer", Breast Cancer Res Treat, 144, pp.353~360 (2014)
- Daskalaki A, "Detection of cytokeratin-19 mRNApositive cells in the peripheral blood and bone marrow of patients with operable breast cancer", Br J Cancer, 101, pp.589~597 (2009)
- Benoy IH, "Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer", Br J Cancer, 94, pp.672~680 (2006)
- Stathopoulou A, "Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer : evaluation of their prognostic significance", J Clin Oncol, 20, pp.3404~3412 (2002)
- Fehm T, "HER2 status of circulating tumor cells in patients with metastatic breast cancer : a prospective, multicenter trial", Breast Cancer Res Treat, 124, pp.403~412 (2010)
- Bidard FC, "Clinical validity of circulating tumour cells in patients with metastatic breast cancer : a pooled analysis of individual patient data", Lancet Oncol, 15, pp.406~414 (2014)
- Meng S, "Circulating tumor cells in patients with breast cancer dormancy", Clin Cancer Res, 10, pp.8152~8162 (2004)
- Fehm T, "Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells", Breast Cancer Res, 11, pp.59~ (2009)